10-Q: Altria Group Reports Strong Q2 Earnings, Boosted by IQOS Deal and Strategic Investments

Altria Group's second-quarter earnings surged, driven by a significant gain from the sale of IQOS commercialization rights and strategic financial maneuvers, despite ongoing challenges in the tobacco market.

Summary

• Altria Group reported a substantial increase in net earnings for the second quarter of 2024, primarily due to a $2.7 billion gain from the sale of IQOS commercialization rights.
• The company's net revenues decreased by 3.6% for the six months ended June 30, 2024, compared to the same period in 2023, mainly due to lower smokeable product revenues.
• Operating income also saw a decrease of 8.0% for the six months ended June 30, 2024, due to lower operating companies income (OCI) and a $354 million non-cash impairment of the Skoal trademark.
• Adjusted diluted earnings per share (EPS) decreased by 1.6% for the six months ended June 30, 2024, despite fewer shares outstanding due to share repurchases.
• The company repurchased 54.1 million shares of its common stock for $2.41 billion in the first half of 2024, funded by proceeds from the sale of a portion of its investment in Anheuser-Busch InBev (ABI).
• Altria's oral tobacco products segment saw a 4.1% increase in net revenues for the six months ended June 30, 2024, driven by higher pricing, but was impacted by a $354 million non-cash impairment of the Skoal trademark.
• The company's smokeable products segment experienced a 4.7% decrease in net revenues for the six months ended June 30, 2024, due to lower shipment volumes.
• Altria's e-vapor business, NJOY, saw its retail share reach 5.5% in the second quarter of 2024, with distribution growing to over 100,000 stores.
• The company's debt-to-Consolidated EBITDA ratio was 2.1x as of June 30, 2024, and it aims to maintain a ratio of approximately 2.0x.
• Altria is targeting a mid-single-digit adjusted diluted EPS compounded annual growth rate in 2028 from a 2022 base.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While the company shows strong earnings growth due to a one-time gain, it also faces significant challenges in its core business and is navigating a complex regulatory environment. The strategic moves and investments are positive, but the underlying market conditions and risks temper the overall sentiment.

Positives

• The sale of IQOS commercialization rights resulted in a significant $2.7 billion pre-tax gain.
• The company successfully executed accelerated share repurchase transactions, reducing the number of outstanding shares.
• NJOY's e-vapor business is showing strong growth, with increased retail share and distribution.
• Altria is maintaining a strong debt-to-Consolidated EBITDA ratio.
• The company is committed to a progressive dividend policy, targeting mid-single-digit growth annually.
• The oral tobacco products segment saw a 4.1% increase in net revenues for the six months ended June 30, 2024.

Negatives

• The company recorded a $354 million non-cash impairment charge for the Skoal trademark.
• Net revenues decreased by 3.6% for the six months ended June 30, 2024, compared to the same period in 2023.
• Operating income decreased by 8.0% for the six months ended June 30, 2024.
• Adjusted diluted EPS decreased by 1.6% for the six months ended June 30, 2024.
• The smokeable products segment experienced a 4.7% decrease in net revenues for the six months ended June 30, 2024, due to lower shipment volumes.
• The company is facing challenges in the tobacco market, including declining cigarette volumes and the growth of illicit e-vapor products.

Risks

• The company faces ongoing litigation and regulatory challenges, including potential product bans and restrictions.
• The tobacco industry is subject to evolving regulations and legislative frameworks that could have a material impact on the business.
• The company is exposed to risks related to illicit trade in tobacco products, including counterfeit and unregulated products.
• Changes in adult tobacco consumer preferences and purchasing behavior could negatively impact sales volumes.
• The company is subject to risks related to the price, availability, and quality of tobacco and other raw materials.
• The company's financial performance is subject to macroeconomic conditions, including inflation and interest rates.
• The company's innovative tobacco products businesses could be materially adversely affected by scientific determinations as to any health risks or negative health consequences associated with the use of e-vapor and other innovative tobacco products.

Future Outlook

Altria aims to deliver a mid-single-digit adjusted diluted EPS compounded annual growth rate in 2028 from a 2022 base, a progressive dividend growth, and a debt-to-Consolidated EBITDA ratio of approximately 2.0x. The company also plans to grow U.S. smoke-free volumes by at least 35% from its 2022 base by 2028 and approximately double its U.S. smoke-free net revenues to $5 billion by 2028.

Management Comments

• Our Vision is to responsibly lead the transition of adult smokers to a smoke-free future.
• We are Moving Beyond Smoking, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices.
• We believe it is a substantial opportunity for adult tobacco consumers, our businesses and society.

Industry Context

The tobacco industry is facing significant challenges, including declining cigarette volumes, the growth of illicit e-vapor products, and evolving consumer preferences. Altria is attempting to navigate these challenges by investing in smoke-free products and strategic financial maneuvers. The company's performance is also influenced by regulatory actions, excise taxes, and macroeconomic conditions.

Comparison to Industry Standards

• Altria's performance in the cigarette market is consistent with the overall industry trend of declining volumes, but the company is maintaining a strong share in the premium segment with Marlboro.
• The growth of NJOY's e-vapor business is a positive sign, but it is still a relatively small player compared to the overall e-vapor market, which is dominated by illicit disposable products.
• The company's oral tobacco products segment is facing increased competition from nicotine pouches, which are growing rapidly, and Altria is attempting to capture market share with its on! brand.
• Altria's financial performance is impacted by the State Settlement Agreements and FDA user fees, which are unique to the tobacco industry and require significant annual payments.
• The company's strategic investments and share repurchase programs are similar to actions taken by other large companies in mature industries to enhance shareholder value.

Legal Proceedings

• Altria is involved in numerous legal proceedings, including product liability, unfair trade practices, antitrust, and patent infringement cases.
• The company is also subject to governmental investigations related to its former investment in JUUL.
• Altria has settled several lawsuits related to JUUL, including a class action lawsuit and cases brought by state attorneys general.

Related Party Transactions

• Altria assigned the exclusive U.S. commercialization rights to the IQOS System to Philip Morris International Inc. (PMI) in exchange for a total cash payment of approximately $2.7 billion (plus interest).

Stakeholder Impact

• Shareholders will benefit from the company's share repurchase program and progressive dividend policy.
• Employees may be affected by the company's strategic shifts and cost-cutting measures.
• Customers will see changes in product offerings and pricing as the company transitions to smoke-free products.
• Suppliers may be impacted by changes in demand for tobacco and other raw materials.
• Creditors are exposed to the company's debt obligations and financial performance.

Next Steps

• The company will continue to execute its 2028 Enterprise Goals, focusing on smoke-free products and strategic investments.
• Altria will continue to monitor and respond to changes in adult tobacco consumer preferences and purchasing behavior.
• The company will continue to engage with the FDA and other regulatory bodies on tobacco product regulations.
• Altria will continue to advocate for a well-regulated U.S. tobacco industry that embraces harm reduction and the enforcement of existing regulatory frameworks.
• The company will continue to monitor the macroeconomic landscape and its impact on adult tobacco consumers.

Key Dates

Keywords

Altria, tobacco, IQOS, NJOY, e-vapor, oral nicotine pouches, share repurchase, financial results, earnings, litigation, regulation, ABI, Marlboro, Skoal, Copenhagen